The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 7.69 — safe zoneOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2026, as EXELIXIS, INC. reports it. History and quarterly detail are in the app.
- Product Gross$3.0B
- Reportable$2.3B
- Product$2.1B
- Cabometyx$2.1B
- License$214.4M
Leadership changes
From EXELIXIS, INC.'s own filings, the day they're filed.
- Amy C. Peterson · Chief Medical Officer · departureeff. 2025-08-29
- Dana T. Aftab · President · appointmenteff. 2025-08-29
- Jacqueline Wright · Directors · departureeff. 2024-03-27
Latest filings
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
- DEF 14A · Annual proxy (pay & governance)2026-04-15
- 8-K · Company announcement2026-02-10
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about EXELIXIS, INC., every answer cited🔒
- The Intelligence Brief — added when EXELIXIS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.